Vanda Pharmaceuticals (VNDA) Expected to Release Earnings on Wednesday

Vanda Pharmaceuticals (NASDAQ:VNDA) is projected to announce its Q3 2026 results after the market closes on Wednesday, October 28th. Analysts expect Vanda Pharmaceuticals to post earnings of ($0.72) per share and revenue of $69.20 million for the quarter. Interested persons may review the information on the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Wednesday, October 28, 2026 at 4:30 PM ET.

Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its quarterly earnings results on Wednesday, August 5th. The biopharmaceutical company reported ($1.04) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.46). Vanda Pharmaceuticals had a negative return on equity of 49.81% and a negative net margin of 127.41%. The company had revenue of $50.53 million during the quarter, compared to analysts’ expectations of $61.92 million. On average, analysts expect Vanda Pharmaceuticals to post ($3.02) EPS for the current fiscal year and ($0.96) EPS for the next fiscal year.

Vanda Pharmaceuticals Price Performance

VNDA stock opened at $4.01 on Monday. Vanda Pharmaceuticals has a one year low of $3.88 and a one year high of $9.94. The firm has a 50-day moving average of $4.94 and a two-hundred day moving average of $5.71. The firm has a market capitalization of $242.44 million, a PE ratio of -0.87 and a beta of 0.69. The company has a current ratio of 1.61, a quick ratio of 1.60 and a debt-to-equity ratio of 0.01.

Analyst Ratings Changes

Several research analysts have recently weighed in on VNDA shares. HC Wainwright reissued a “buy” rating and issued a $20.00 target price on shares of Vanda Pharmaceuticals in a research report on Monday, October 5th. Weiss Ratings restated a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a research report on Thursday, October 15th. Zacks Research lowered shares of Vanda Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Tuesday, October 6th. Oppenheimer initiated coverage on shares of Vanda Pharmaceuticals in a research note on Wednesday, September 23rd. They issued an “outperform” rating and a $10.00 price objective for the company. Finally, B. Riley Financial reiterated a “buy” rating and set a $12.00 price objective (down from $17.00) on shares of Vanda Pharmaceuticals in a research report on Monday, August 10th. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, Vanda Pharmaceuticals currently has an average rating of “Hold” and an average target price of $13.08.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing therapies for central nervous system disorders and other conditions with significant unmet medical needs. Founded in 2003 and headquartered in Washington, DC, the company primarily serves patients and healthcare providers in the United States, with certain products and commercial rights extending to international markets.

Vanda’s marketed products include Hetlioz (tasimelteon), a treatment for Non-24-Hour Sleep-Wake Disorder in totally blind individuals and nighttime sleep disturbances associated with Smith-Magenis syndrome.